QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Q32 Bio Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$7.79+0.27 (+3.59%)
Close on Oct 19, 2026
- Market cap
- $158.47M
- P/E (TTM)
- 3.2
- Dividend yield
- –
Q32 Bio Inc. revenue by segment
By business segment
By product or service
By region
From the segment and revenue-disaggregation notes of Q32 Bio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.